Genotoxicity studies on benzimidazole retinoids

Area of Science:

• Pharmacology
• Genetics
• Biochemistry

Background:

• Retinoids are vital compounds regulating cell growth and differentiation, but clinical use is limited by toxicity.
• Synthetic retinoids are explored for therapeutic potential, necessitating evaluation of their safety and efficacy.
• Understanding retinoid genotoxicity and effects on drug resistance mechanisms is crucial for developing new cancer therapies.

Purpose of the Study:

• To synthesize and evaluate three benzimidazole retinoid derivatives (BITN, BITNm, BITNe) for genotoxicity in human lymphocytes.
• To assess the impact of these derivatives and all-trans retinoic acid (ATRA) on sister chromatid exchange (SCE) rates.
• To investigate the effects of these compounds on glutathione S-transferase (GST) activity, a marker for anticancer drug resistance.

Main Methods:

• Sister chromatid exchange (SCE) analysis in human lymphocyte cultures was used to assess genotoxicity.
• The induction of glutathione S-transferase (GST) activity was measured using CDNB as a substrate.
• Benzimidazole retinoid derivatives (BITN, BITNm, BITNe) and ATRA were tested at concentrations of 10(-6) M and 10(-5) M.

Main Results:

• Benzimidazole retinoids did not significantly induce SCEs. BITN reduced SCEs by 20% at 10(-6) M, indicating a protective effect.
• ATRA increased SCEs by 35% at 10(-5) M.
• BITN, BITNm, and BITNe induced GST activity at 10(-5) M, with BITNe showing the highest induction (62%) at this concentration. BITNe also induced GST activity at 10(-6) M.

Conclusions:

• Benzimidazole retinoids exhibit a favorable genotoxic profile, with BITN showing potential protective effects against SCE induction.
• The tested benzimidazole retinoids can induce GST activity, suggesting a role in modulating cellular defense mechanisms against anticancer drugs.
• These findings support further investigation of benzimidazole retinoids as potentially safer alternatives to existing retinoids in cancer therapy.